Peter Voorhees, MD - Three Rs for Modern Myeloma Care: Delivering the Right Treatment for the Right Patient at the Right Time With Antibody and BCMA Platforms

Previous Episode: Kun "Kevin" Xiang, MD, PhD - Anticoagulation Therapy in NVAF: A Quality Improvement Initiative

Next Episode: Geoffrey L. Chupp, MD / Autumn Burnette, MD, FACAAI - Leveraging the Power of Targeted Biologic Therapy in Severe Asthma: Do You Know How and For Whom?

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/VRK865. CME/MOC/AAPA/IPCE credit will be available until July 1, 2025 .

Three Rs for Modern Myeloma Care: Delivering the Right Treatment for the Right Patient at the Right Time With Antibody and BCMA Platforms

In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Multiple Myeloma. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported through educational grants from Bristol Myers Squibb, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC (which are both Johnson & Johnson companies), and Sanofi.

Disclosure information is available at the beginning of the video presentation.

Peter Voorhees, MD - Three Rs for Modern Myeloma Care: Delivering the Right Treatment for the Right Patient at the Right Time With Antibody and BCMA Platforms

PeerView Heart, Lung & Blood CME/CNE/CPE Audio Podcast